Bayer HealthCare announced that Gadavist (gadobutrol injection), a macrocyclic gadolinium-based contrast agent, has been approved for intravenous use in diagnostic magnetic resonance imaging (MRI) in ...
Bayer announced that the Food and Drug Administration (FDA) has approved Gadavist (gadobutrol) injection for use with magnetic resonance angiography (MRA) to evaluate known or suspected supra-aortic ...
WHIPPANY, N.J., Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved Gadavist ® (gadobutrol) injection for use with magnetic resonance angiography (MRA) to evaluate ...
CAD is the most common type of heart disease in the United States, as up to one half of middle aged men and one third of middle aged women in the US are at risk of developing CAD during their lifetime ...
WHIPPANY, N.J. - Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Gadavist® (gadobutrol) injection for use in cardiac magnetic resonance (MR) imaging to assess myocardial ...
The US Food and Drug Administration (FDA) has approved the first gadolinium-based MRI contrast agent, gadobutrol (Gadavist, Bayer Healthcare), for patients under 2 years of age. The injected agent is ...
Bayer’s Gadavist has become the first imaging agent approved in the US to detect blockages in the hearts of patients with known or suspected coronary artery disease (CAD). The magnetic resonance ...
Gadavist® Imaging Bulk Package is supplied as 604.72mg/mL of gadobutrol in 30mL and 65mL multidose containers. The Food and Drug Administration (FDA) has approved the Gadavist® (gadobutrol; Bayer ...
The FDA expanded the approvals of Bayer’s Gadavist MRI contrast agent, clearing it to help gauge the blood supply of the heart muscle as well as the rates of myocardial perfusion at rest and during ...
Fresenius Kabi is offering Gadobutrol injection, which is a generic of Bayer's Gadavist. It is used in magnetic resonance imaging procedures. "Fresenius Kabi is pleased to introduce Gadobutrol ...
Bayer HealthCare has received approval from the US Food and Drug Administration (FDA) for a new indication for Gadavist (gadobutrol) injection for intravenous use with MRI of the breast to assess the ...
Bayer’s Gadavist has become the first imaging agent approved in the US to detect blockages in the hearts of patients with known or suspected coronary artery disease (CAD). The magnetic resonance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback